Abstract
Objective
To evaluate the efficacy and safety of recombinant human interleukin-11 (rhlL-11) for the chemotherapy-induced thrombocytopenia in patients with gastrointestintal cancer.
Methods
It was an opened and non-randomized controlled clinical study. When the platelet counts was under 75 × 109/L after chemotherapy, rhlL-11 was administered 25 μg/(kg·d) as a daily SC injection last for 7–14 days, or discontinued when platelet counts ≥ 100 × 109/L.
Results
Seventy-six patients were enrolled into this study. The treatment group and the control group had thirty-eight cases, respectively. The mean recovery time to PLT ≥ 100 × 109/L was 8.1 days in treatment group, while in control group was 12.2 days (P < 0.01). Moreover, the mean recovery time from PLT ≤ 50 × 109/L to ≥ 100 × 109/L was 8.9 days in treatment group, while in control group was 12.9 days (P < 0.05). There was a statistical difference between the two groups. Major side effects included edema, fever, articular muscle soreness, but they were all mild and well tolerable.
Conclusion
rhlL-11 can be safely and effectively used for the treatment of chemotherapy-induced thrombocytopenia in patients with gastrointestinal cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Zhu YH, Pang HM. Clinical application of IL-11. Foreign Med Sci Oncol Sect (Chinese), 2005, 32: 845–848.
Isaacs C, Robert NJ, Bailey FA, et al. Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin. J Clin Oncol, 1997, 15: 3368–3377.
Cantor SB, Elting LS, Hudson DV Jr, et al. Pharmacoeconomic analysis of oprelvekin (recombinant human interluekin-11) for secondary prophylaxis of thrombocytopenia in solid tumor patients receiving chemotherapy. Cancer, 2003, 97: 3099–3106.
Chu DT, Xu BH, Song ST, et al. Recombinant human interleukin 11 (Mega) promotes thrombopoiesis in cancer patients with chemotherapy-induced myelosuppression. J Exp Hematol (Chinese), 2001, 9: 314–317.
Sun XF, Guan ZZ, Huang H, et al. Clinical study of rhlL-11 for prevention and treatment of chemotherapy-induced thrombocytopenia. Chin J Cancer (Chinese), 2002, 21: 892–895.
Cao JN, Xu LG, Wu Q, et al. Phase II study of recombinant human interleukin-11 treatment for chemotherapy-induced thrombocytopenia. China Oncol (Chinese), 2005, 15: 141–144.
Li L, Xu CG, Wang XW, et al. Effectiveness and safety of rhlL-11 in the treatment of chemotherapy-induced thrombocytopenia. Chin J Oncol (Chinese), 2005, 27: 377–379.
Wang XY, Feng FY, Song ST, et al. Phase II clinical trial on China manufactured recombinant human interleukin-11 derivative in the prevetion and treatment of chemotherapy-induced thrombocytopenia. Chin J Oncol (Chinese), 2005, 27: 373–376.
Huang J, Xu BH, Cai RG, et al. A randomized trial of recombinant human interleukin-11 in the prophylaxis of thrombocytopenia due to chemotherapy. Chin J Clin Oncol (Chinese), 2003, 30: 258–260.
Xie XD, Zheng ZD, Liu DW, et al. Clinical research on the effects of rhlL-11 in preventing and curing thrombocytopenia caused by chemotherapy. Chin J Pract Inter Med (Chinese), 2006, 26: 286–287.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Li, J., Shen, L., Li, Y. et al. Recombinant human interleukin-11 for treatment of chemotherapy-induced thrombocytopenia in patients with gastrointestinal cancer. Chinese German J Clin Oncol 6, 450–452 (2007). https://doi.org/10.1007/s10330-007-0096-2
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10330-007-0096-2